VLA - Viralytics Limited
- Thread starter Robroy
- Start date
-
- Tags
- viralytics limited vla
- Joined
- 30 June 2007
- Posts
- 7,200
- Reactions
- 1,225
Biotechs are definitely flavour of the week/month and VLA has a really nice story unfolding. See their website.
The chart shows small real bodies and long upper wicks with a definite uptrend, which all spells "insto accumulation". One definitely needs to be careful about entry price (because they love thumpingit back down), but I'd say 10-10.5c would be reasonable for today. So long as mining stocks stay out of favour, and I think they will for some time, this should continue on to 12c (previous high) without any problems whatsoever. Whether it breaks through that might depend on anns (or lack thereof) in line with market expectations. Timing will be important. FDA approval pending.
The chart shows small real bodies and long upper wicks with a definite uptrend, which all spells "insto accumulation". One definitely needs to be careful about entry price (because they love thumpingit back down), but I'd say 10-10.5c would be reasonable for today. So long as mining stocks stay out of favour, and I think they will for some time, this should continue on to 12c (previous high) without any problems whatsoever. Whether it breaks through that might depend on anns (or lack thereof) in line with market expectations. Timing will be important. FDA approval pending.
- Joined
- 30 June 2007
- Posts
- 7,200
- Reactions
- 1,225
Managed Fund boss: "How are we going with VLA?"
junior: "We have filled about 1/2 of the volume we need. No one is selling to us"
boss: "Keep the volume up, even if you have to buy and sell to yourself all day"
junior: "yes we're doing that, but we are making up almost all of the day's trades. No one is selling to us".
boss: "ok thump the price down 10% and see what happens"
junior: *click*....waits.....
boss: "what happened? any reaction? any stops triggered?"
junior: "no we just cleared all our own bids".
boss: "fuc.k. If we push it down too far, these traders are going to be all over it and buy up OUR stock. Just keep at it. We may need to take out every price level up to 20c if we don't get any more stock today".
junior: "ok"
boss: "do you know how to do that?"
junior: "yes, we enter the order seconds before VLA opens. It gaps up to 20c, we fill the bid side and then start selling heavily into those bids so that it doesn't attract traders. Then sell it back to about 12 cents".
boss: "exactly. Bloody traders, give the irrits. Only we should have access to this company. Who do they think they are?"
.... and so on.
junior: "We have filled about 1/2 of the volume we need. No one is selling to us"
boss: "Keep the volume up, even if you have to buy and sell to yourself all day"
junior: "yes we're doing that, but we are making up almost all of the day's trades. No one is selling to us".
boss: "ok thump the price down 10% and see what happens"
junior: *click*....waits.....
boss: "what happened? any reaction? any stops triggered?"
junior: "no we just cleared all our own bids".
boss: "fuc.k. If we push it down too far, these traders are going to be all over it and buy up OUR stock. Just keep at it. We may need to take out every price level up to 20c if we don't get any more stock today".
junior: "ok"
boss: "do you know how to do that?"
junior: "yes, we enter the order seconds before VLA opens. It gaps up to 20c, we fill the bid side and then start selling heavily into those bids so that it doesn't attract traders. Then sell it back to about 12 cents".
boss: "exactly. Bloody traders, give the irrits. Only we should have access to this company. Who do they think they are?"
.... and so on.
skc
Goldmember
- Joined
- 12 August 2008
- Posts
- 8,277
- Reactions
- 329
Not as excited as the sellers today?! High 11c low 7.6c for a tidy gap close.
What did the fund manager said to the junior today?
- Joined
- 30 June 2007
- Posts
- 7,200
- Reactions
- 1,225
Same as the other day. "Flush those friggin' day traders out of my company".
I watched the trading for most of the morning and there was nothing 'organic' about it. Private traders just do not trade that way. If a stock is primed to run, and has strong sentiment, it runs. Traders allow it to run until it gets overbought. Or in the case of a very weak Ords (such as we have at the moment), you end up with a long upper wick on a small white bodied candle. The trading was just so negative and inhibitory, and it achieved its aim.
I watched the trading for most of the morning and there was nothing 'organic' about it. Private traders just do not trade that way. If a stock is primed to run, and has strong sentiment, it runs. Traders allow it to run until it gets overbought. Or in the case of a very weak Ords (such as we have at the moment), you end up with a long upper wick on a small white bodied candle. The trading was just so negative and inhibitory, and it achieved its aim.
For those of you who have woken to find that VLA is an invalid code on ASX etc, rest easy. As a nervous investor I called the company this morning and Mr Delahunty assures us that all is well and the company will be active on the code VLADA for approx. 8-10 days and revert back to VLA.
- Joined
- 24 December 2010
- Posts
- 1,154
- Reactions
- 50
Relevant:
It's a tempting idea and one on the cutting edge of a new medical research field called oncolytic virotherapy. Could the common cold cure cancer?
Except that the idea is not really new at all. The classical Greek physician Hippocrates is often credited with the saying: ''Give me the power to create a fever and I shall cure any disease.''
More than 2500 years later modern scientists, including a team from the University of Newcastle, are proving the theory has merit.
...
Associate Professor Darren Shafren of the University of Newcastle has been looking at the phenomenon for the better part of 15 years. ''Even though a lot of the cases seemed anecdotal, there was something in it,'' he says. ''This phenomenon has always been there but with the latest tools and technologies we have, we can match the right virus with the right cancer.''
Shafren is the chief scientific officer with a company called Viralytics, which has been conducting trials using a virus to treat cancer patients. His work is focused on the coxsackievirus, one of the causes of the common cold.
''It's a small virus, it's about one-billionth of the size of a table tennis ball,'' he says. ''If you look at it under an electron microscope, it looks a bit like a Ferrero Rocher chocolate. The beauty with this particular virus is that it attacks cancer cells.''
The virus is attracted to a certain molecule that is found in abnormally high numbers on cancer cells. While a healthy cell might have five or six of these particular molecules, a cancer cell would have 10,000.
''So the virus comes past, recognises all these molecules and all of a sudden it just sticks on there,'' Shafren says.
''Not only does the virus actively seek out cancer cells [but] once it's inside the cell it replicates until it eventually bursts the cell.''
Once the cell breaks open, the patient's antibodies move in, alerting the immune system to the presence of cancer cells.
''So one virus goes in, 200 come out and they they potentially can go and infect other cells,'' Shafren says.
''If they get into the bloodstream, they can be carried to other areas of the body and infect other cancer cells at a distant site.''
Attacking those tiny clusters of cancer cells, known as micrometastases, before they have progressed is the ultimate goal of the treatment, but such studies could take years.
''If you look at a one-centimetre tumour, there is something in the order of 10 billion cancer cells in there but it's the size of a marble,'' Shafren says. ''Micrometastases are a collection of maybe a couple of hundred cells. You'll never see them - they're too small. But the virus can detect those cells and do a mopping operation.''
Having made this discovery, Shafren and his team then needed to work out which cancer cells the virus liked to kill most.
Preliminary research shows the common cold virus has a taste for melanoma - the third-most common type of cancer in Australia - but Shafren is also looking at how viruses affect cancers of the breast, prostate, pancreas and lung.
He shies away from the term ''holy grail'' but he believes virotherapy could give cancer patients better quality of life.
http://www.smh.com.au/technology/sci-tech/could-this-virus-cure-cancer-20120421-1xdtf.html
It's a tempting idea and one on the cutting edge of a new medical research field called oncolytic virotherapy. Could the common cold cure cancer?
Except that the idea is not really new at all. The classical Greek physician Hippocrates is often credited with the saying: ''Give me the power to create a fever and I shall cure any disease.''
More than 2500 years later modern scientists, including a team from the University of Newcastle, are proving the theory has merit.
...
Associate Professor Darren Shafren of the University of Newcastle has been looking at the phenomenon for the better part of 15 years. ''Even though a lot of the cases seemed anecdotal, there was something in it,'' he says. ''This phenomenon has always been there but with the latest tools and technologies we have, we can match the right virus with the right cancer.''
Shafren is the chief scientific officer with a company called Viralytics, which has been conducting trials using a virus to treat cancer patients. His work is focused on the coxsackievirus, one of the causes of the common cold.
''It's a small virus, it's about one-billionth of the size of a table tennis ball,'' he says. ''If you look at it under an electron microscope, it looks a bit like a Ferrero Rocher chocolate. The beauty with this particular virus is that it attacks cancer cells.''
The virus is attracted to a certain molecule that is found in abnormally high numbers on cancer cells. While a healthy cell might have five or six of these particular molecules, a cancer cell would have 10,000.
''So the virus comes past, recognises all these molecules and all of a sudden it just sticks on there,'' Shafren says.
''Not only does the virus actively seek out cancer cells [but] once it's inside the cell it replicates until it eventually bursts the cell.''
Once the cell breaks open, the patient's antibodies move in, alerting the immune system to the presence of cancer cells.
''So one virus goes in, 200 come out and they they potentially can go and infect other cells,'' Shafren says.
''If they get into the bloodstream, they can be carried to other areas of the body and infect other cancer cells at a distant site.''
Attacking those tiny clusters of cancer cells, known as micrometastases, before they have progressed is the ultimate goal of the treatment, but such studies could take years.
''If you look at a one-centimetre tumour, there is something in the order of 10 billion cancer cells in there but it's the size of a marble,'' Shafren says. ''Micrometastases are a collection of maybe a couple of hundred cells. You'll never see them - they're too small. But the virus can detect those cells and do a mopping operation.''
Having made this discovery, Shafren and his team then needed to work out which cancer cells the virus liked to kill most.
Preliminary research shows the common cold virus has a taste for melanoma - the third-most common type of cancer in Australia - but Shafren is also looking at how viruses affect cancers of the breast, prostate, pancreas and lung.
He shies away from the term ''holy grail'' but he believes virotherapy could give cancer patients better quality of life.
http://www.smh.com.au/technology/sci-tech/could-this-virus-cure-cancer-20120421-1xdtf.html
greggles
I'll be back!
- Joined
- 28 July 2004
- Posts
- 4,460
- Reactions
- 4,494
It looks like VLA is getting taken over by Merck & Co., Inc. at $1.75 a share. Not a bad premium on yesterday's close of 62.5c. Viralytics shareholders laughing all the way to the bank today.
- Joined
- 27 June 2010
- Posts
- 4,147
- Reactions
- 309
On June 21st, 2018, Viralytics Limited (VLA) was removed from the ASX's official list in accordance with Listing Rule 17.11, following implementation of the scheme of arrangement between the Company and its shareholders in connection with the acquisition of all the issued capital in the Company by Merck Sharp & Dohme (Holdings) Pty Ltd (a wholly owned subsidiary of Merck & Co., Inc.).